publication date: Nov. 10, 2017

CMS plan to slash $1.6 billion from 340B program will reduce discounts on cancer drugs

By Matthew Bin Han Ong

Hospitals enrolled in the 340B program stand to lose up to $1.6 billion in Medicare Part B reimbursements through upcoming cuts to the drug pricing program, according to a final rule by the Centers for Medicare and Medicaid Services.

Published Nov. 1, the final Outpatient Prospective Payment System regulation would move $1.6 billion out of the drug discount program, cutting reimbursement to 340B hospitals for separately payable drugs by nearly  30 percent.

Part B payments would drop from the current level of average sales price plus 6 percent to ASP minus 22.5 percent.

“CMS is implementing this policy in a budget neutral manner by offsetting the projected decrease in drug payments of $1.6 billion by redistributing an equal amount for non-drug items and services across the OPPS,” according to a fact sheet published by CMS. “CMS may revisit these policies for [calendar year] 2019 and is especially interested in exploring policies addressing the needs of safety net hospitals, which play a critical role in serving the most vulnerable populations.”

The OPPS, which was put in place in 2000, pays for designated hospital outpatient services and some Medicare Part … Continue reading CMS plan to slash $1.6 billion from 340B program will reduce discounts on cancer drugs

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.